V.P. Prod. Dev. and Project Management

Dr. Rininger possesses over 18 years of experience in basic biomedical research and biopharmaceutical product development. Most recently, he was the program manager for the advanced development and commercialization of a recombinant hemagglutinin-based subunit vaccine for influenza (Flublok®) under a $147M government contract. This encompassed planning and leading a cross-functional team in the execution of tasks encompassing all areas of recombinant vaccine development (process development, formulation development and stability, pre-clinical toxicology quality control, process, and facility validation, manufacturing process transfer, regulatory affairs, and clinical development.

Furthermore, he has the experience and solid skills in international business development and business strategy from serving as Director, Business Development at Protein Sciences Corporation. In this role, he established and led the process development, manufacturing, and regulatory (CMC) aspects for four recombinant programs to enter clinical trials.